Long Term Study With B2036-PEG
NCT00143416 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 16
Last updated 2008-07-29
Summary
Primary objective: To investigate the efficacy and safety of Pegvisomant in Japanese patients with acromegaly.
Conditions
Interventions
- DRUG
-
Pegvisomant
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Pfizer CT.gov Call Center · Pfizer
Study Design
- Allocation
- NON_RANDOMIZED
- Purpose
- TREATMENT
- Masking
- NONE
- Model
- SINGLE_GROUP
Eligibility
- Min Age
- 20 Years
- Max Age
- 75 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-04-30
- Completion
- 2007-07-31
Countries
- Japan
Study Locations
More Related Trials
-
Phase IV Clinical Study of Pegylated Somatropin (PEG Somatropin) to Treat Growth Hormone Deficiency Children
NCT02314676 ·Status: UNKNOWN ·Phase: PHASE4
-
Tissue Biomarker for Pegvisomant Action
NCT01261000 ·Status: COMPLETED ·Phase: NA
-
Long Term Study of Genotropin (Somatropin) for Short Children Born Small for Gestational Age (SGA)
NCT01859949 ·Status: COMPLETED ·Phase: PHASE4
-
Canadian Pegvisomant Compassionate Study In Acromegalic Patients
NCT00151437 ·Status: COMPLETED ·Phase: PHASE4
-
Pegylated Somatropin (PEG Somatropin) in the Treatment of Children With Growth Hormone Deficiency
NCT03249480 ·Status: UNKNOWN ·Phase: PHASE4
-
Acromegaly Treatment Quality of Life Study
NCT01732406 ·Status: COMPLETED
-
Study to Assess the Efficacy and Safety of Repeated Administration of BIM 23A760 in Patients With Acromegaly
NCT00994214 ·Status: TERMINATED ·Phase: PHASE2
-
Effect of Pegvisomant on GH/IGF-I Relationship in GHD
NCT00468624 ·Status: TERMINATED ·Phase: NA
-
Growth Retardation In Children With Special Pathological Conditions Or Disease
NCT00163215 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy of Octreotide Acetate and Cabergoline in Patients With Acromegaly
NCT00376064 ·Status: COMPLETED ·Phase: PHASE4
-
Efficiency and Safety Study of Pegylated Somatropin to Treat Growth Hormone Deficiency Children
NCT01342146 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Evaluate the Long-Term Safety and Efficacy of Paltusotine for the Treatment of Acromegaly (ACROBAT Advance)
NCT04261712 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Treatment of Adults With Growth Hormone Deficiency
NCT00596037 ·Status: COMPLETED ·Phase: PHASE3
-
Treatment Of Short Stature With Genotropin In Children Born Small For Gestational Age Until Final Height
NCT00174421 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of Pegylated Somatropin to Treat Growth Retardation Caused by Endogenous Growth Hormone Deficiency in Children
NCT03290235 ·Status: UNKNOWN ·Phase: PHASE4
-
Pegvisomant And Sandostatin LAR Combination Study
NCT00068029 ·Status: COMPLETED ·Phase: PHASE4
-
Pasireotide LAR and Pegvisomant Study in Acromegaly
NCT02668172 ·Status: UNKNOWN ·Phase: PHASE4
-
Phase II Study With ITF2984 in Acromegalic Patients
NCT02111044 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate the Efficacy and Safety of Sandostatin LAR at High Dose or in Combination Either With GH-receptor Antagonist or Dopamine-agonist in Acromegalic Patients
NCT01278342 ·Status: COMPLETED ·Phase: PHASE4
-
Special Investigation Of Genotropin Long Follow-Up For Patients With A Small For Gestational Age "Scoped for Japanese"
NCT01897766 ·Status: COMPLETED
-
Change in Quality of Life After Addition of Weekly 40 mg Pegvisomant/Placebo in Controlled Acromegalic Patients
NCT00642720 ·Status: COMPLETED ·Phase: PHASE4
-
Treatment of Adults With Growth Hormone Deficiency
NCT00294619 ·Status: COMPLETED ·Phase: PHASE3
-
Effect of Somatropin on Left Ventricular Mass in Growth Hormone Deficient Adult Patients
NCT01562834 ·Status: COMPLETED ·Phase: PHASE4
-
Safety and Efficacy of Pegvisomant in Children With Growth Hormone Excess
NCT03882034 ·Status: COMPLETED ·Phase: PHASE3
-
Pharmacokinetics and Pharmacodynamics of ACP-001 (TransCon PEG hGH)
NCT01010425 ·Status: COMPLETED ·Phase: PHASE1